Enovis Co. (NYSE:ENOV) Receives $67.00 Consensus PT from Analysts

Shares of Enovis Co. (NYSE:ENOV) have been given an average rating of “Moderate Buy” by the nine research firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $67.00.

A number of equities analysts have commented on the stock. Evercore ISI dropped their price objective on shares of Enovis from $62.00 to $58.00 and set an “outperform” rating for the company in a research note on Tuesday, October 1st. JMP Securities assumed coverage on Enovis in a research report on Thursday, October 3rd. They issued an “outperform” rating and a $62.00 price target for the company. Finally, Needham & Company LLC reissued a “buy” rating and set a $65.00 price objective on shares of Enovis in a research note on Thursday, November 7th.

Enovis Price Performance

Shares of Enovis stock opened at $45.65 on Friday. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. Enovis has a 52 week low of $38.27 and a 52 week high of $65.03. The stock’s 50-day simple moving average is $44.38 and its 200-day simple moving average is $44.56. The company has a market capitalization of $2.55 billion, a price-to-earnings ratio of -20.84 and a beta of 1.94.

Enovis (NYSE:ENOV) last issued its earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.11. The firm had revenue of $505.22 million during the quarter, compared to analyst estimates of $504.44 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. Enovis’s revenue for the quarter was up 21.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.56 earnings per share. As a group, analysts expect that Enovis will post 2.79 earnings per share for the current fiscal year.

Institutional Trading of Enovis

Hedge funds have recently bought and sold shares of the stock. Retirement Systems of Alabama raised its holdings in Enovis by 10.1% in the third quarter. Retirement Systems of Alabama now owns 67,846 shares of the company’s stock worth $2,921,000 after purchasing an additional 6,239 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Enovis by 9.5% during the 3rd quarter. Geode Capital Management LLC now owns 921,437 shares of the company’s stock worth $39,678,000 after acquiring an additional 80,165 shares in the last quarter. Barclays PLC lifted its position in Enovis by 16.1% during the third quarter. Barclays PLC now owns 368,488 shares of the company’s stock valued at $15,864,000 after acquiring an additional 51,151 shares during the last quarter. MML Investors Services LLC boosted its stake in Enovis by 17.2% in the third quarter. MML Investors Services LLC now owns 44,179 shares of the company’s stock valued at $1,902,000 after acquiring an additional 6,476 shares in the last quarter. Finally, First National Bank of Omaha grew its holdings in Enovis by 3.0% in the third quarter. First National Bank of Omaha now owns 53,866 shares of the company’s stock worth $2,319,000 after purchasing an additional 1,575 shares during the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.